Maltofer®
Milan Lukáš Orcid.org 1
+ Affiliation
To read this article in full, please register for free on this website.
Benefits for subscribers
Benefits for logged users
Literature
1. Státní ústav pro kontrolu léčiv. SPC přípravku Maltofer tablety SUKL 9.5.2012 (č.j. 41555/2012). [online]. Dostupné z: http://www.sukl.cz/.
2. Dietzfelbinger H. Bioavailability of bi‑ and trivalent oral iron preparations. Investigations of iron absorption by postabsorption serum iron concentrations curves. Arzneimittelforschung 1987; 37(1A): 107–112.
3. Nielsen P, Gabbe EE, Fischer R et al. Bioavailability of iron from oral ferric polymaltose in humans. Arzneimittelforschung 1994; 44(6): 743–748.
4. Jacobs P, Wormald L. The bioavailability of an iron polymaltose complex for treatment of iron deficiency. J Med 1979; 10(4): 279–285.
5. Geisser P, Burckhardt S. The pharmacokinetics and pharmacodynamics of iron preparations. Pharmaceutics 2011; 3(1): 12–33. doi: 10.3390/pharmaceutics3010012.
6. Geisser P. Safety and efficacy of iron(III)-hydroxide polymaltose complex – a review of over 25 years experience. Arzneimittelforschung 2007; 57(6A): 439–452.
7. Jacobs P, Johnson G, Wood L. Oral iron therapy in human subjects, comparative absorption between ferrous salts and iron polymaltose. J Med 1984; 15(5–6): 367–377.
8. Kaltwasser JP, Werner E. Assessment of bioavailability of oral iron preparations in man. In: Forth W (ed). Iron. Bioavailability, absorption, utilization 1993: 31–57.
9. Kaltwasser JP, Werner E, Niechzial M. Bioavailability and therapeutic efficacy of bivalent and trivalent iron preparations. Arzneimittelforschung 1987; 37(1A): 122–129.
10. Andrews NC, Schmidt PJ. Iron homeostasis. Annu Rev Physiol 2007; 69: 69–85.
11. Ganz T. Hepcidin, a key regulator of iron metabolism and mediator of anemia of inflammation. Blood 2003; 102(3): 783–788.
12. EMEA guideline. CPMP/EWP/QWP/1401/98 London 2001.